Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $0.3948
Latest analyst grade actions
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 29.35 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 23.88 | Oscillator | Neutral |
| Williams %R (14) | -86.33 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.04 (Hist 0.00) | Oscillator | Buy |
| Average Directional Index (14) | 39.11 (+DI 12.1 / -DI 23.0) | Trend | Strong Sell |
| EMA 20 | 0.45 | MA | Strong Sell |
| SMA 20 | 0.45 | MA | Strong Sell |
| EMA 50 | 0.57 | MA | Strong Sell |
| SMA 50 | 0.52 | MA | Strong Sell |
| SMA 200 | 1.09 | MA | Strong Sell |
Stock news · updated daily
Bone Biologics Corp. (NASDAQ: BBLG - Get Free Report) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totaling 36,999 shares, a decrease of 76.4% from the August 15th total of 156,590 shares. Approximately 1.4% of the shares of the stock are sold short. Based
BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that six hospital sites in Australia are now under agreement to participate in its first-in-human pilot clinical trial of NB1, the Company's rhNELL-1-based bone graft product for spinal fusion.
BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | -0.43 | -0.43 | Beat 0.0% | — |
| May 14, 2026 | -0.43 | -0.43 | Beat 0.0% | — |
| Mar 2, 2026 | -0.34 | -0.58 | Miss -70.6% | — |
| Nov 14, 2025 | -1.23 | -0.37 | Beat 69.9% | — |
| Aug 14, 2025 | -0.58 | -1.33 | Miss -129.3% | — |
| May 13, 2025 | -3.24 | -0.32 | Beat 90.1% | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 25-NSE | Oct 13, 2026 | 2026-10-13 10:07:30 | View |
| 4 | Sep 30, 2026 | 2026-09-30 17:14:56 | View |
| 4 | Sep 30, 2026 | 2026-09-30 17:12:42 | View |
| 4 | Sep 30, 2026 | 2026-09-30 17:09:07 | View |
| 4 | Sep 30, 2026 | 2026-09-30 17:06:43 | View |
| 8-K | Sep 29, 2026 | 2026-09-29 17:00:43 | View |
| 8-K | Sep 16, 2026 | 2026-09-16 17:00:39 | View |
| DEF 14A | Aug 28, 2026 | 2026-08-28 17:27:26 | View |
| PRE 14A | Aug 18, 2026 | 2026-08-18 17:00:13 | View |
| 10-Q | Aug 14, 2026 | 2026-08-14 17:00:47 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BBLG | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.2x | -15.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.3x | EPS est. -1.23 | Elevated |
| Price / Book | 0.2x | 4.6x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | 1.4x | -13.6x | Discount |
| Return on equity | -57.9% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.00 | 0.00 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -28.09 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 28, 26 | Gagnon Robert E. | director | A-Award | 113,896 @ $0.50 | $56.95K |
| Sep 28, 26 | Angle Siddhesh Rajendra | director | A-Award | 113,896 @ $0.50 | $56.95K |
| Sep 28, 26 | Meikle Phillip Terry Ii | director | A-Award | 113,896 @ $0.50 | $56.95K |
| Sep 28, 26 | Stroever Bruce | director | A-Award | 113,896 @ $0.50 | $56.95K |
| Jan 8, 26 | Walsh Deina H | officer: Chief Financial Officer | A-Award | 8,335 @ $1.55 | $12.92K |
| Jan 8, 26 | Frelick Jeff | officer: Chief Executive Officer | A-Award | 16,668 @ $1.55 | $25.84K |
| Jun 4, 25 | Meikle Phillip Terry Ii | director | A-Award | 62,894 @ $0.88 | $55.35K |
| Jun 4, 25 | Angle Siddhesh Rajendra | director | A-Award | 62,894 @ $0.88 | $55.35K |